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A B S T R A C T
Introduction: Traditional Chinese medicine (TCM) plays an important role in the treatment of
dyslipidemia and it is important to identify an objective index for the TCM syndrome. This study
focused on exploring the correlation between TCM syndrome and the serum concentration of
adiponectin (APN) and peroxynitrite (ONOO) in dyslipidemia patients.
Methods: Cross-sectional study design was used. Patients with dyslipidemia were assigned with
corresponding TCM scores and their APN and ONOO serum content measured. We also explored the
characteristics of APN and ONOO in different TCM syndromes and their relationship between patient’s
TCM scores.
Results: The results indicated the serum levels of APN and ONOO were higher for those people with an
Excess Syndrome than for those with a Deﬁciency Syndrome (P < 0.01). In Deﬁciency Syndrome, the
clinical TCM scores showed negative correlation with and APN (r = 0.46, P < 0.01), and positive with
ONOO (r = 0.58, P < 0.01). In Excess Syndrome, the TCM scores showed negative correlation with APN
(r = 0.72, P < 0.01), and positive with ONOO (r = 0.50, P < 0.01).
Conclusions: As the serum levels of APN and ONOO appeared to be correlated with the TCM scores, these
parameters could be potentially be used as objective and standardized biomarkers for TCM syndrome
differentiation.
ã 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contents lists available at ScienceDirect
European Journal of Integrative Medicine
journa l home page : www.e l sev ier .com/euj im1. Introduction
Dyslipidemia is a common disease characterised by abnormali-
ty in blood lipids such as the total cholesterol (TC), triglycerides
(TG), high-density lipoprotein cholesterol (HDL-C) and low-
density lipoprotein cholesterol (LDL-C), etc. [1]. A number of
studies have shown that dyslipidemia is an important independent
risk factor in vascular diseases such as myocardial infarction,
stroke, etc., therefore, it is crucial to prevent these diseases by$ This issue belongs to the Special Issue on Methodological Challenges in Whole
Systems Research.
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4.0/).active treatment for patients with dyslipidemia [2–5], and basic
and clinical research on dyslipidemia are active worldwide.
Traditional Chinese medicine plays an important role in the
treatment of dyslipidemia in China, and the key to successful
treatment is the accuracy of TCM syndrome differentiation after
disease diagnosis. TCM syndrome is a diagnostic concept which is
unique to TCM, and summarizes the pathology in terms of the
location, causes, nature and trend of the disease, and provides the
pathological essence of the current state of the disease [6]. Good
TCM syndrome differentiation requires diagnosis by a TCM expert
practitioner. The study of dyslipidemia using TCM syndromes is
becoming a hot topic in research [7–9].
To identify the occurrence of TCM syndrome, this must be
supported by objective data and the internal mechanism
indiscernible. Highly speciﬁc objective biomarkers would bele under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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severity. The aim was to determine whether microscopic indicators
available through blood tests could be potentially reliable evidence
to assist TCM syndrome differentiation.
The clinical course of dyslipidemia is highly associated with the
degree of the vascular damage, and the evaluation of TCM
treatment focuses more on the changes of the related indices.
Studies have shown that clinical efﬁcacy of TCM in treating
dyslipidemia can be quantiﬁed and elucidated by the changes of
indexes such as vasoactive substances, plasma endothelin,
homocysteine, carotid ultrasound indexes, blood viscosity, antiox-
idant enzyme activity, etc. [10–13]. Previous study has found
relevance between primary dyslipidemia patients with cardiovas-
cular risk stratiﬁcation and TCM syndrome [14].
The above discussion indicates that vascular damage is closely
related with the severity of the disease, but few studies have
focused on the relationship between TCM syndrome and vascular
damage. APN plays multiple roles in protecting the vascular
endothelium, and it can inhibit the generation of oxidized low-
density lipoprotein (Ox-LDL) induced by reactive oxygen species
(ROS) in endothelial cell culture [15]. APN plays a role in protecting
the vascular system by its anti-inﬂammatory effects, and the
effects of reducing oxidative stress and inhibiting the formation of
atherosclerotic plaque [16]. ONOO is an active free radical
possessing high oxidative ability, and it can cause the endothelial
damage by protein oxidation or protein nitration [17]. ONOO is
highly cytotoxic, and its nitriﬁcation can lead to endothelial
dysfunction by causing oxidative stress and tissue damage [18].
The variations of APN and ONOO concentration in serum are
closely associated with the endothelial damage and repair, and
recognized as potential substances in reﬂecting the human
endothelial damage degree [19,20]. They both are involved in the
endothelial damage and repair process induced by dyslipidemia.
TCM syndrome is considered to be the pathological and
physiological response of the body at a certain stages of the
disease. Through literature review, we found that APN, ONOO
could reﬂect the state of disease and the pathological and
physiological changes of the patient with dyslipidemia, and to
some extent, the concept is in accordance with the notion of TCM.
Therefore, we hypothesize that the changes of APN and ONOO
in serum levels could reﬂect the features of different TCM
syndrome of patients with dyslipidemia. Thus, APN and ONOO
could be promising biomarkers for TCM syndrome differentiation,
and helpful in the care and monitoring of dyslipidemia patients.
A cross-sectional study was carried out to explore APN and
ONOO serum levels characteristics present in patients with
dyslipidemia who had different TCM syndromes. The aim was to
correlate serum levels of APN, ONOOwith the TCM scores, which
reﬂects the severity of the TCM syndrome.
2. Materials and methods
2.1. Materials
2.1.1. Subjects
A total of 193 inpatients were enrolled from Dongzhimen
Hospital, Beijing University of Chinese Medicine (Beijing, China)
between April 2014 and February 2015. All selected subjects
fulﬁlled the diagnosis of dyslipidemia and were in accordance with
the inclusion criteria. Ethical approval was granted by the Ethics
Committee of Dongzhimen Hospital, Beijing University of Chinese
Medicine (Beijing, China), and the approval number is ECPJ-BDY-
2014-15. The ethical application, enrolling 200 subjects, was
submitted to the medical ethics committee of the Dongzhimen
Hospital of Beijing University of Chinese medicine in March 2014.
The application was approved on 1st April 2014 after ethicalreview. The study has been reviewed and approved by Chinese
Clinical Trial Register, and the registration number is ChiCTR-OCS-
14004487. Informed consent was obtained by each patient
enrolled in this study.
2.2. Diagnostic standard
(1) Diagnostic standard for dyslipidemia.
The diagnostic standards for dyslipidemia referred to the
Guidelines on Prevention and Treatment of Blood Lipid Abnormal-
ity in Chinese Adults [21]. The diagnosis of dyslipidemia was based
on the presence of one or more of the following criteria: high TG
(>1.7 mmol/L), high TC (>5.18 mmol/L), high LDL cholesterol
(>3.37 mmol/L), and low HDL cholesterol (<1.04 mmol/L) levels.
(2) Diagnostic standards of TCM syndromes for Deﬁciency
Syndrome and Excess Syndrome.
The TCM syndrome differentiation of the enrolled subjects were
strictly in accordance with The Guiding Principle of Clinical Research
on New Traditional Chinese Drugs for Dyslipidemia [22].
This research of traditional Chinese medicine (TCM) syndrome
identiﬁcation strictly follow the traditional diagnosis methods,
including looking, hearing and smelling, asking, pulse examination
and palpation, collectively called the “four examinations”. The four
examinations provide information about different disease aspects,
such as chief symptoms and signs and case history. Symptoms
include the patient’s subjective feeling. Signs include the abnormal
conditions found through examination. Symptoms and signs are
manifestations reﬂecting a disease or syndrome, which is the
foundation for disease or syndrome differentiation.
2.3. Characteristics of deﬁciency syndrome
The principal symptoms and signs include susceptibility to
colds, cold limbs, dizziness, lassitude, hypodynamia, diarrhea. The
secondary symptoms and signs include pale and tender tongue
with white tongue coating, deep and thread pulse.
2.4. Characteristics of excess syndrome
The principal symptoms and signs include obesity, heavy-
headedness, chest distress, vomiting of mucus, heavy limbs and
limb numbness. The secondary symptoms and signs include
palpitation, insomnia, tastelessness in mouth, loss of appetite,
swollen tongue with greasy and slippery tongue coating, wiry and
slippery pulse.
TCM syndrome classiﬁcation was based on the clinical TCM
scores according to the symptom rating scale in the Guiding
Principle. The two enrolled doctors have a senior professional title,
more than 5 years of clinical experience, and received standard
training on the subject at the beginning of the study to ensure the
authority and consistency of the syndrome differentiation results.
2.4.1. Inclusion criteria
The inclusion criteria were as follows: (1) subjects with
dyslipidemia in accordance with the diagnostic standards and
TCM syndrome diagnostic standards, (2) ranged in age from 20 to
80, (3) who signed the informed consent, and (4) without lipid-
lowering medications.
2.4.2. Exclusion criteria
The exclusion criteria were composed of four criteria and a
patient was excluded if they fails on any of the criteria. Mentioned
criteria were: (1) secondary dyslipidemia (causes of dyslipidemia
include but not limited to hypothyroidism, nephrotic syndrome,
chronic renal failure, liver diseases, diseases of the hematopoietic
system, adrenal-corticosteroid or contraceptive-drug induced
Table 1
The demographic information of the subjects.a
Items Demographic information
Gender
Males (case (%)) 74 (38.3%)
Females (case (%)) 119 (61.7%)
TCM syndrome
Deﬁciency syndrome (case (%)) 97 (50.3%)
Excess syndrome (case (%)) 96 (49.7%)
Age (years) 56.68  12.31
Temperature (degree Celsius) 36.34  0.39
Systolic blood pressure (mmHg) 129.90  17.07
Diastolic blood pressure (mmHg) 78.19  9.75
Heart rate (beats per minute) 74.25  8.65
Body mass index (kg/m2) 25.86  3.52
a Data was presented as mean  SD. Gender and TCM syndrome were displayed as
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or unable to extend tongue for tongue observation; (3) patients
with psychosis or unable to answer questions properly; (4)
patients with acute infectious diseases or in the acute disease
states (such as acute myocardial infarction, acute cerebrovascular
disease, etc.), as well as pregnant women.
2.5. Research methods
2.5.1. Grouping
Cross-sectional study design was used, and a total of 193 sub-
jects, including 97 patients with Deﬁciency Syndrome and
96 patients with Excess Syndrome, were enrolled according to
the sequence of hospitalization.
2.5.2. Collection of TCM clinical information
Signs and symptoms by the TCM four examinations method
were collected using clinical questionnaires. Scores were given by
the severity of the signs and symptoms. The data were collected by
two independent TCM practitioners.
2.5.3. Sample collection and APN and ONOO determination
(1) Sample collection: blood samples of inpatients were collected
after a minimum 8-h overnight fasting the next morning when
enrolled. After routine tests, blood serum was separated from
the remained blood sample and stored in EP tubes. The tubes
were kept in refrigerator at the temperature of 80 C and
prepared for detection of APN and ONOO.
(2) APN and ONOO determination: routine blood biochemical
index were detected in the inpatient laboratory of the hospital.
The EP tubes containing the serum samples were safely
protected in dry ice to ensure the constant temperature and
shipped to Shanghai Lianshuo Biological Technology Co., Ltd.
The APN and ONOO contents in the serum samples were
measured by ELISA. The tests were carried out in single-blind with
one parallel hole for each sample to ensure the reality and
reliability of the results. The ELISA kits were AMEKO, Shanghai,
CHN.
2.6. Quality control methods
We have developed a standard operation protocol for the
research program and trained all the investigators accordingly.
Prior to data collection, two investigators need to obtain consent
from each patients before they were enrolled into the study. TCM
diagnosis and questionnaires were used to ensure the consistency
of the collected data. Assigned investigators were responsible for
sample collection, storage, data input and analysis. The regular
veriﬁcation of the integrity of the clinical data and research record
ensured the reliability of the collected data.
2.7. Statistical analysis
Data were analyzed using the Statistical Package for Social
Sciences (SPSS version 17.0). Raw data were analyzed for Gaussian
distribution and variance homogeneity. The mean  standard
deviation (SD) values were calculated for variables with Gaussian
distribution, and groups were contrasted by the independent
sample Student’s t test. Non-Gaussian variables were represented
by Median (interquartile range) and differences between groups
analyzed by nonparametric tests. Count data are expressed as
frequency (percentage). The correlation analysis was performed by
the Spearman’s rank test. Values were considered signiﬁcantly
different if p < 0.05.3. Results
3.1. The demographic information of the subjects
A total of 193 (74 males and 119 females) patients were included
in the study. Ninty seven showed deﬁciency syndrome and
96 excess syndrome. Patients ranged from 23 to 80 y (average
56.6  12.2). There was no statistical difference in the age,
temperature, blood pressure, and heart rate of the patients with
excess syndrome or deﬁciency syndrome, and the accuracy and
objectivity of the research can be guaranteed. For BMI, there was a
signiﬁcant statistical difference between patients with excess
syndrome and those with deﬁciency syndrome. The demographic
data is shown in Tables 1 and 2.
3.2. The comparison of serum levels of APN and ONOO
The statistic results indicated the serum level of APN was higher
in Excess Syndrome than that in Deﬁciency Syndrome, and
signiﬁcant difference was observed. The serum levels of ONOO
were higher in Excess Syndrome than that in Deﬁciency Syndrome
and signiﬁcant difference was observed (Fig. 1 and Table 3).
3.3. Comparisons between different TCM syndrome and serum levels of
biomarkers
Inpatients were classiﬁed into 3 groups (mild, moderate,
severe) based on their TCM scores which were devided into
quartiles. Subjects were ordered by their TCM scores from low to
high, and the ﬁrst 25% of the subjects were in the mild group, the
following 50% in the moderate, and the last 25% in the severe
group. In deﬁciency syndrome, there were 30 in mild group, 45 in
moderate group, 22 in severe group. In excess syndrome, there
were 28 in mild group, 46 in moderate group, 22 in severe group. In
both deﬁciency syndrome and excess syndrome, the serum levels
of APN and ONOO showed statistical difference between the
3 groups. The mild group had the highest APN concentration and
the lowest ONOO concentration (Fig. 2(a) and (b)).
Subjects were grouped into 3 subgroups according to their APN
and ONOO serum concentrations, respectively for each syndrome
groups. The subjects were ordered by their APN and ONOO
concentrations from low to high values getting 4 lists of patients.
Each list was divided into 3 equal to have the mild, moderate and
severe subgroups. In the deﬁciency syndrome group, according to
the APN concentration, there were 19 in the mild subgroup, 50 in
moderate and 28 in the severe subgroup. And according to the
ONOO concentration, there were 42 in the mild subgroup, 44 in
moderate, and 11 in the severe subgroup. In the excess syndromecase number (%).
Fig. 1. The comparison of serum biomarker levels between TCM syndromes.
(a): The comparison of serum levels of APN between Deﬁciency syndrome and Excess syndrome of TCM syndrome.
(b): The comparison of serum levels of ONOO between Deﬁciency syndrome and Excess syndrome of TCM syndrome.
Notes: **P < 0.01 versus Deﬁciency syndrome.
Table 2
The comparison of TCM syndrome in demographic information (mean  SD).
Characteristics Age (years) Temperature (degree
Celsius)
Systolic blood pressure
(mmHg)
Diastolic blood pressure
(mmHg)
Heart rate (beats per
minute)
Body mass index (kg/
m2)
Deﬁciency
syndrome
56.92  13.42 36.33  0.39 128.63  17.71 76.80  10.39 73.56  8.49 24.99  3.23
Excess syndrome 56.44  11.15 36.35  0.39 131.19  16.39 79.59  8.89 74.96  8.80 26.68  3.60#
# P < 0.01 versus Deﬁciency syndrome group.
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mild subgroup, 29 in moderate and 30 in the severe subgroup. And
according to the ONOO concentration, there were 48 in the mild
subgroup, 31 in moderate, and 17 in the severe subgroup. There
were statistical differences between each subgroup for the two
syndrome groups. For deﬁciency syndrome, the TCM scores were
high in APN and ONOOmild subgroups, and the TCM scores were
low in APN and ONOO severe subgroups. For excess syndrome,
the TCM scores were low in APN and ONOOmild subgroups, and
the TCM scores were high in APN and ONOO severe subgroups.
(Fig. 2(c)–(f))
3.4. The analysis indicated signiﬁcantly correlation between clinical
TCM scores of patients with dyslipidemia and serum levels of APN and
ONOO
In Deﬁciency Syndrome, the clinical TCM scores showed
negative correlation with the APN values (r = 0.46, P < 0.01),
and positive correlation with the ONOO values (r = 0.58, P < 0.01).
In Excess Syndrome, the clinical TCM scores showed negative
correlation with the APN values (r = 0.72, P < 0.01), and positive
correlation with the ONOO values (r = 0.50, P < 0.01). Details are
shown in Fig. 3.Table 3
The comparison of TCM syndrome in serum levels of APN and ONOO.
APN(mg/mL) ONOO (nmol/L)
Deﬁciency syndrome 26.08  7.15 264.06  81.16
Excess syndrome 31.00  8.57# 339.23  107.57#
# P < 0.01 versus Deﬁciency syndrome group.4. Discussion
In clinical pratice, TCM syndrome differentiation is widely used
in treating dyslipidemia and can improve clinical effectiveness.
TCM provides advantages in treating dyslipidemia but the key to
effective clinical treatments relies on the improved diagnosis of a
speciﬁc TCM syndrome. This requires the expert clinical experi-
ence of the TCM practitioners. The use of objective, quantitative
health parameters can be helpful to differentiate between TCM
syndromes. The degree of vascular damage is closely related to the
severity of dyslipidemia disease, and the APN and ONOO
concentration are highly associated with vascular endothelial
injury and repair. To some extent, APN and ONOO also reﬂect the
pathophysiology of vascular damage, it is possible to study the
objectiﬁcation of TCM syndrome of dyslipidemia from the serum
levels of APN and ONOO.
Firstly, the characteristics in the serum levels of APN and
ONOO were different for different TCM syndrome groups in
patients with dyslipidemia.
APN is produced by adipose tissue and plays an important role
in maintaining the metabolism and the inner balance of vascular
system. The APN serum levels could be used as biological markers
to reﬂect the pathophysiological changes of atherosclerosis [23–
26]. APN has multi-protective effects on vascular endothelial cells,
since the serum level of APN could reﬂect the severity of the
vascular injury, which could help explain the negative correlation
between serum concentration of APN and vascular injury.
ONOO is a free radical with strong oxidatvei power, and it can
cause endothelial injury by protein oxidation or nitration [27].
Thus, the serum levels of ONOO can reﬂect the severity of vascular
damage to some extent and have positive correlation with it.
Deﬁciency Syndrome is a typical TCM syndrome due to the lack
of vital energy (Zheng Qi) for protection [28]. Since APN is an
Fig. 2. The corresponding relations between different TCM syndromes levels and serum biomarkes at different concentrations.
(a): The comparison of the different TCM syndrome levels in APN concentration.
(b): The comparison of the different TCM syndrome levels in ONOO concentration.
(c): The comparison of APN concentration in Deﬁciency syndrome.
(d): The comparison of APN concentration in Excess syndrome.
(e): The comparison of ONOO concentration in Deﬁciency syndrome.
(f): The comparison of ONOO concentration in Excess syndrome.
Notes: DDP < 0.01 versus mild level, ##P < 0.01 versus middle level, #P < 0.05 versus middle level, **P < 0.01 versus low level.
J. Chen et al. / European Journal of Integrative Medicine 8 (2016) 973–979 977endogenous vascular protection factor [29], the comparison of APN
between the two TCM syndrome groups showed that the serum
levels of APN in Deﬁciency Syndrome is signiﬁcantly lower than in
Excess Syndrome, indicating the APN serum concentration is an
objective parameter to corroborate the TCM deﬁciency factor.
Excess Syndrome is a typical TCM syndrome caused by the
accumulation of pathological phlegm and dampness in the body.
ONOO is a pathological product which can cause severe vascular
endothelial cell damage. The serum levels of ONOOwere higher in
Excess Syndrome than that in Deﬁciency Syndrome, indicating the
ONOO serum concentration is an objective parameter to
corroborate the TCM excess factor.
Secondly, the serum levels of APN and ONOO could reﬂect the
severity of the TCM syndrome as APN showed a negative
correlation with the severity but was positive for ONOO.
For further study on the differences of TCM syndrome in
patients with dyslipidemia, TCM syndrome quantiﬁcation isneeded as well as classiﬁcation. Hence, we quantiﬁed the TCM
syndrome based on the clinical TCM scores according to the
symptom rating scale. The TCM scores were ideal carriers for data
analysis and met the requirements of the scientiﬁc expression.
The serum concentration of APN is negatively correlated with
the incidence of cardiovascular disease [30–33]. Dyslipidemia is
usually accompanied with severe endothelial dysfunction, and its
mechanism is closely related to the NO dyspoiesis [34–36]. Thus,
the serum levels of ONOO can reﬂect the severity of vascular
damage to some extent and have positive correlation with it.
Phlegm is the key factor in Excess Syndrome. The vascular
damage seems to become severer with the accumulation of
phlegm. Deﬁciency Syndrome is lack of vital energy (Zheng Qi) for
protection. The clinical TCM scores of the two TCM syndrome in the
study had close relationship with the serum levels of APN and
ONOO respectively. The scores of the two TCM syndromes had a
negative correlation with serum levels of APN but positive
Fig. 3. The Correlation on serum biomarker levels and TCM syndromes.
(a): The Correlation between serum APN levels and the scores of Deﬁciency syndrome.
There is a negative correlation (r < 0.01) between serum APN levels and the scores of Deﬁciency syndrome.
(b): The Correlation between serum ONOO levels and the scores of Deﬁciency syndrome.
There is a positive correlation (r = 0.58, P < 0.01) between serum ONOO levels and the scores of Deﬁciency syndrome.
(c): The Correlation between serum APN levels and the scores of Excess syndrome.
There is a negative correlation (r = 0.72, P < 0.01) between serum APN levels and the scores of Excess syndrome.
(d): The Correlation between serum ONOO levels and the scores of Excess syndrome.
There is a positive correlation (r = 0.50, P < 0.01) between serum ONOO levels and the scores of Excess syndrome.
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severity of the TCM syndrome, and in this study, the TCM scores
elevate with the descending of the APN concentration or the
ascending of the ONOO concentration. With the increase of the
TCM scores, many symptoms such as obesity, heaviness of head,
chest distress, nausea, abundant sputum, limb heaviness, etc., are
more likely to be seen in subjects with excess syndrome. On the
other hand, symptoms such as aversion to cold, cold extremities,
dizziness, lassitude, loose stools, etc., are more likely to be seen in
subjects with deﬁciency syndrome. The variations in the character-
istics of the two biomarkers in serum levels were consistent with
the TCM ethiology and pathogenesis, which could possibly deﬁnethe scientiﬁc character and feasibility of TCM syndrome differen-
tiation. Discussing the material basis of TCM syndrome form a new
perspective will enrich the connotation of TCM syndrome
differentiation.
The limitations in our cross-sectional study were as follows:
ﬁrstly, all the investigators were trained according to the standard
operation protocol to ensure the accuracy and consistency of the
collected data, but information bias and selection bias were
inevitable due to the methodological deﬁciencies of the cross-
sectional study. Secondly, this cross-sectional study only analyzed
the related indices in different syndromes dyslipidemia patients,
and it was not enough to deduce th53e causality between different
J. Chen et al. / European Journal of Integrative Medicine 8 (2016) 973–979 979syndromes and dyslipidemia indices, and to infer the pathological
mechanism of the occurrence and development of the different
syndromes.
5. Conclusion
The APN and ONOO concentration varies between different
TCM syndrome groups of dyslipidemia patients. They are
correlated with the TCM scores and can reﬂect the discrepancy
and severity of the TCM syndrome. APN and ONOO are promising
standard and objective biomarkers for TCM syndrome differentia-
tion.
Conﬂict of interests
The authors declare that they have no conﬂict of interests.
Funding
Supported by Fundamental Research Funds for the Central
Universities, Graduate Student Researchers Project (independent
topic selection) of Beijing University of Chinese Medicine (2014-
JYBZZ-XS-135) and Specialized Research Fund for the Doctoral
Program of Higher Education of China (20110013110002).
References
[1] S. Antonopoulos, Third report of the National Cholesterol Education Program
(NCEP) expert panel on detection: evaluation, and treatment of high blood
cholesterol in adults (Adult Treatment Panel III) ﬁnal report, Circulation 106
(25) (2002) 3143–3421.
[2] D.Y. Hu, J.H. Wang, The status quo of Chinese prevention and treatment of
dyslipidemia, Chin. J. Pract. Internal Med. 29 (1) (2009) 2–4.
[3] T.J. Wilt, H.E. Bloomﬁeld, R. MacDonald, et al., Effectiveness of statin therapy in
adults with coronary heart disease, Arch. Intern. Med. 164 (13) (2004) 1427–
1436.
[4] A.R. Tall, An overview of reverse cholesterol transport, Eur. Heart J. (Suppl. A)
(1998) 31–35.
[5] G. Assmann, P. Cullen, H. Schulte, The Munster Heart Study (PROCAM). Results
of follow-up at 8 years, Eur. Heart J. (1998) 2–11.
[6] Z.Q. Guo, Practical Diagnosis in Traditional Chinese Medicine, Shanghai science
and Technology Press, 2013, pp. 148–149.
[7] S. Sun, H. Xu, L. Ngeh, The evaluation of Chinese therapeutic food for the
treatment of moderate dyslipidemia, Evid.-Based Complementary Altern.
Med. 2012 (2012) 508683.
[8] M. Guo, Y. Liu, Z.Y. Gao, et al., Chinese herbal medicine on dyslipidemia:
progress and perspective, Evid.-Based Complementary Altern. Med. 2014
(2014) 163036.
[9] Q.H. Shang, Z.L. Liu, K.J. Chen, et al., A systematic review of xuezhikang, an
extract from red yeast rice, for coronary heart disease complicated by
dyslipidemia, Evid.-Based Complementary Altern. Med. 2012 (2012) 636547.
[10] P.S. Shi, H.W. Liu, The effects of Jiangzhi Oral Liquid on the inﬂammatory
cytokines and vasoactive substances in patients with hyperlipidemia, Chin. J.
Integr. Tradit. Western Med. 32 (8) (2012) 1141–1143.
[11] J.P. Wang, R.H. Fan, Y. Wang, et al., Treatment of hyperlipoidemia by xiaozhi
capsule: a clinical efﬁcacy research, Zhongguo Zhong Xi Yi Jie He Za Zhi 33 (6)
(2013) 736–740.[12] Y. Lei, Z.H. Wang, J.G. Liu, Study on rules of TCM syndrome in patients with
dyslipidemia and its objectization, Zhongguo Zhong Xi Yi Jie He Za Zhi 27 (12)
(2007) 1074–1077.
[13] D.H. Li, L.L. Jin, J.F. Bian, H.Y. Liang, P.H. Huang, H. Su, Effect of zhimaikang
granules on lipid peroxidation of hyperlipidemia patients with syndrome of
phlegm turbidity retention, J. Tradit. Chin. Med. 51 (1) (2010) 34–36.
[14] Y.M. Lou, F. Li, P. Han, S. Qi, Correlation of TCM syndromes with cardiovascular
risk classiﬁcation and serum lipids of primary dyslipidemia, China J. Trad. Chin.
Med. Pharm. 28 (6) (2013) 1893–1895.
[15] H. Motoshima, X. Wu, K. Mahadev, B.J. Goldstein, Adiponectin suppresses
proliferation and superoxide generation and enhances eNOS activity in
endothelial cells treated with oxidized LDL, Biochem. Biophys. Res. Commun.
315 (2) (2004) 264–271.
[16] Z. Weidong, K.K.Y. Cheng, P.M. Vanhoutte, et al., Vascular effects of
adiponectin: molecular mechanisms and potential therapeutic intervention,
Clin. Sci. 114 (5) (2008) 361–374.
[17] A. Tedgui, Z. Mallat, Cytokines in atherosclerosis: pathogenic and regulatory
pathways, Physiol. Rev. 86 (2) (2006) 515–581.
[18] S. Wu, L. Wang, A.M. Jacoby, et al., Ultraviolet B light-induced nitric oxide/
peroxynitrite imbalance in keratinocytes-implications for apoptosis and
necrosis, Photochem. Photobiol. 86 (2) (2010) 389–396.
[19] A.H. Sprague, R.A. Khalil, Inﬂammatory cytokines in vascular dysfunction and
vascular disease, Biochem. Pharmacol. 78 (6) (2009) 539–552.
[20] G.K. Hansson, Inﬂammation, atherosclerosis, and coronary artery disease, N.
Engl. J. Med. 352 (16) (2005) 1685–1695.
[21] JCfDCG P, ToDi A, Chinese guidelines on prevention and treatment of
dyslipidemia in adults, Zhonghua Xin Xue Guan Bing Za Zhi 35 (5) (2007)
390–419.
[22] X.Y. Zheng, The Guiding Principle of Clinical Research on New Traditional
Chinese Drugs for Dyslipidemia, China Medical Science Press, 2002, pp. 85–89.
[23] S. Li, H.J. Shin, E.L. Ding, et al., Adiponectin levels and risk of type 2 diabetes: a
systematic review and meta-analysis, JAMA 302 (2) (2009) 179–188.
[24] R. Adya, B.K. Tan, H.S. Randeva, Differential effects of leptin and adiponectin in
endothelial angiogenesis, J. Diabetes Res. 2015 (2015) 648239.
[25] M. Rienstra, J.X. Sun, S.A. Lubitz, et al., Plasma resistin,adi-ponectin, and risk of
incident atrial ﬁbrillation: the Fram-ingham Offspring Study, Am. Heart J. 163
(1) (2012) 119–124.
[26] T. Pischon, C.J. Girman, G.S. Hotamisligil, et al., Plasma adiponectin levels and
risk of myocardial infarction in men, JAMA 291 (14) (2004) 1730–1737.
[27] A. Tedgui, Z. Mallat, Cytokines in atherosclerosis: pathogenic and regulatory
pathways, Physiol. Rev. 86 (2) (2006) 515–581.
[28] H.C. Li, X.P. Li, X.Y. Li, Syndrome of Chinese Medicine, China Medical Science
Press, 2013, pp. 158.
[29] A. Floreani, A. Variola, G. Niro, et al., Plasma adiponectin levels in primary
biliary cirrhosis: a novel perspective for link between hypercholesterolemia
and protection against atherosclerosis, Am. J. Gastroenterol. 103 (8) (2008)
1959–1965.
[30] N. Sattar, G. Wannamethee, N. Sarwar, et al., Adiponectin and coronary heart
disease a prospective study and meta-analysis, Circulation 114 (7) (2006) 623–
629.
[31] T. Pischon, C.J. Girman, G.S. Hotamisligil, et al., Plasma adiponectin levels and
risk of myocardial infarction in men, JAMA 291 (14) (2004) 1730–1737.
[32] M. Ai, S. Otokozawa, B.F. Asztalos, et al., Adiponectin: an independent risk
factor for coronary heart disease in men in the Framingham Offspring Study,
Atherosclerosis 217 (2) (2011) 543–548.
[33] D.J. Stott, P. Welsh, A. Rumley, et al., Adipocytokines and risk of stroke in older
people: a nested case–control study, Int. J. Epidemiol. 38 (1) (2009) 253–261.
[34] R. Li, W.B. Lau, X.L. Ma, Adiponectin resistance and vascular dysfunction in the
hyperlipidemic state, Acta Pharmacol. Sin. 31 (10) (2010) 1258–1266.
[35] R. Li, M. Xu, X. Wang, et al., Reduced vascular responsiveness to adiponectin in
hyperlipidemic rats-mechanisms and signiﬁcance, J. Mol. Cell. Cardiol. 49 (3)
(2010) 508–515.
[36] R. Li, W.Q. Wang, H. Zhang, et al., Adiponectin improves endothelial function in
hyperlipidemic rats by reducing oxidative/nitrative stress and differential
regulation of eNOS/iNOS activity, Am. J. Physiol.-Endocrinol. Metab. 293 (6)
(2007) E1703–E1708.
